Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff

Issued on behalf of Oncolytics Biotech Inc.

VANCOUVER, BC, Jan. 14, 2026 — Equity-Insider.com News Commentary – The precision oncology market is entering a major growth phase, projected to expand from about $110 billion toward roughly $225.65 billion by 2032^[1]. That surge is being accelerated as Big Pharma moves to mitigate a looming $170 billion patent cliff that could erode blockbuster revenue through 2030^[2]. The scramble for registration-ready assets is a key part of the 2026 investment thesis for Oncolytics Biotech Inc. (NASDAQ: ONCY), Nurix Therapeutics (NASDAQ: NRIX), Erasca (NASDAQ: ERAS), Foghorn Therapeutics (NASDAQ: FHTX), and ORIC Pharmaceuticals (NASDAQ: ORIC).

The broader precision medicine market is forecast to reach $537.17 billion by 2035 as targeted biotech platforms become highly sought acquisition targets^[3]. A primary catalyst is the FDA’s accelerated approval pathway, which has delivered clinically meaningful results across many solid tumors and has enabled faster commercialization of response-focused drugs^[4]. For many investors, molecularly targeted “precision killers” are now the most valuable infrastructure plays in modern oncology.

Oncolytics Biotech: building toward registration-directed programs

Oncolytics Biotech Inc. (NASDAQ: ONCY) has been strengthening its operational and statistical leadership while advancing pelareorep into multiple registration-directed programs in gastrointestinal cancers.

The company recently announced the appointments of John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics, bringing deep expertise in late-stage oncology trial execution and regulatory strategy. McAdory joins from CG Oncology, where he led late-stage development programs for oncolytic virus therapies. Wu previously led biostatistics at Morphic Therapeutics through an acquisition by Eli Lilly and directed statistical strategy for multiple Phase 3 oncology programs at Takeda. Both executives have direct experience with complex registration trials and global regulatory interactions.

Jared Kelly, CEO of Oncolytics Biotech, said, “John’s background running complex, late-stage oncology trials makes him exceptionally well-suited to lead Oncolytics’ next phase of execution. As we progress toward pivotal and registration-enabling studies in anal, pancreatic, and colorectal cancers, his experience will be critical to ensuring disciplined execution, speed, and regulatory alignment.”

These appointments complete a broader executive buildout following Kelly’s promotion to CEO and the addition of Chief Business Officer Andrew Aromando. The team additions and board expansions (including experts from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center) position Oncolytics for accelerated clinical development across multiple indications.

The company is focused on advancing pelareorep toward potential accelerated approval in anal cancer after reporting third-line data with a 29% objective response rate—nearly triple historical benchmarks in a setting with no FDA-approved options. The median duration of response reached approximately 17 months. In second-line or later settings, pelareorep achieved a ~30% response rate, more than double the 13.8% benchmark for the only FDA-approved immunotherapy in that setting, with a median duration of response of 15.5 months versus 9.5 months for standard care.

Oncolytics has also secured FDA alignment on its Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, positioning it to launch the only immunotherapy registration trial currently planned for that disease.

CONTINUED… Read this and more about Oncolytics Biotech at: https://equity-insider.com/2025/03/18/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/

Other industry developments

In other recent industry developments and market news:

Nurix Therapeutics (NASDAQ: NRIX) outlined 2026 goals to execute a pivotal program for its BTK degrader bexobrutideg, including Phase 2 and confirmatory Phase 3 studies to support global registration in relapsed/refractory chronic lymphocytic leukemia. Nurix initiated the DAYBreak CLL-201 pivotal Phase 2 study in October 2025 and plans to initiate the confirmatory Phase 3 trial DAYBreak CLL-306 in 2026, comparing bexobrutideg monotherapy to pirtobrutinib. The company presented new clinical data at the 67th American Society of Hematology Annual Meeting showing an 83% objective response rate in a heavily pretreated CLL population. Nurix reported pro forma cash and investments of $663.8 million following an October 2025 equity offering.

Erasca (NASDAQ: ERAS) announced promising early clinical data for ERAS-0015, demonstrating multiple confirmed and unconfirmed partial responses across tumor types with various RAS mutations during dose escalation. ERAS-0015 showed ongoing responses at doses as low as 8 mg once daily. With INDs cleared in May 2025 for ERAS-0015 and ERAS-4001, Erasca is enrolling ahead of plan and expects initial Phase 1 monotherapy data in the first half of 2026, with expansion and combination cohorts in the second half of 2026.

Foghorn Therapeutics (NASDAQ: FHTX) raised $50 million in an equity financing with BVF Partners, Deerfield Management, Flagship Pioneering, and a leading biotech mutual fund, priced at a ~30% premium to the closing stock price on January 9, 2026. The Phase 1 dose-escalation trial of FHD-909, targeting SMARCA4-mutant cancers (with a focus on NSCLC), is enrolling globally. Foghorn’s selective CBP degrader program (potential in ER-positive breast cancer) is on track to be IND-ready in 2026; the company reported cash, equivalents and marketable securities of $208.9 million, extending its runway into 1H 2028.

ORIC Pharmaceuticals (NASDAQ: ORIC) reported potential best-in-class Phase 1b data for rinzimetostat showing broad efficacy and differentiated safety in metastatic castration-resistant prostate cancer. The allosteric PRC2 inhibitor achieved PSA50 responses in 55% of patients and PSA90 in 20% when combined with AR inhibitors; 59% of patients achieved ctDNA clearance. ORIC also presented enozertinib Phase 1b data with a 67% ORR in first-line EGFR exon 20 mutation patients and 100% intracranial ORR in measurable CNS disease. The company expects combination dose optimization data for rinzimetostat in 1Q 2026 and to initiate its first global Phase 3 registrational trial in mCRPC in 1H 2026.

Sources

SOURCES CITED:

1. https://www.newstrail.com/precision-oncology-market-scope/
2. https://www.cnbc.com/2026/01/07/big-pharma-race-to-snap-up-biotech-assets-as-170-billion-patent-cliff-looms.html
3. https://www.precedenceresearch.com/precision-medicine-market
4. https://www.oncologynurseadvisor.com/news/fda-accelerated-approval-oncology-drugs-improved-patient-survival/

Contact

CONTACT:
Equity Insider
Email: [email protected]
Phone: (604) 265-2873

Disclaimer

DISCLAIMER: Nothing in this publication should be considered personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor a recommendation to buy or sell any security. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. This compensation constitutes a conflict of interest as to our ability to remain objective. Individuals are strongly encouraged not to use this publication as the basis for any investment decision. The owner/operator of MIQ owns shares of Oncolytics Biotech Inc., which were purchased in the open market, and may buy or sell shares at any time. All material disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement. While information is believed to be reliable, it is not guaranteed. Individuals should verify information independently. Investing in securities carries a high degree of risk; you may lose some or all of your investment.

Logo: https://mma.prnewswire.com/media/2840019/5717750/Equity_Insider_Logo.jpg